Media Information
Mid-Atlantic Bio
For more information, or to request for a media pass, please contact:
Alicia Moran
Email: Alicia@brightlinemedia.com
Work: 703-739-2424 x110
Cell: 410-991-7027
For more information, please contact media@midatlanticbio.org or call 866-482-7691.
Mid-Atlantic Bio Facts and Stats
Mid-Atlantic Bio will attract more than 1000 attendees, including:
- Senior executives from more than 200 companies
- More than 50 investment funds
- Senior faculty from the region’s top academic and research institutions
- Attendees from more than 30 states and numerous countries around the world
Baltimore-Based CSA Medical Raises $12.6 Million in First Round
Baltimore — CSA Medical, a Baltimore-based developer of devices that flash freeze and treat diseased tissue inside the body, said on Tuesday it has raised $12.6 million in its first round of funding, which included a new investment from Blue Heron Capital. The company, which said it already is in discussions with investors about a potential second round, plans to use the proceeds to support the launch of its technology platform. The technology, which uses an endoscopic tool to spray extreme cold liquid nitrogen, is currently being used to treat esophageal disease at nearly 80 U.S. cancer centers and academic teaching hospitals.
http://www.csamedical.com
http://www.prnewswire.com/news-releases/csa-medical-completes-126-million-series-a-financing-with-additional-venture-investment-from-blue-heron-capital-125410798.html
Rockville-Based Supernus Raises $42 Million to Prepare Drugs for Launch
Rockville, Md. — Supernus Pharmaceuticals, a Rockville-based specialty pharmaceutical firm developing treatments for disorders of the central nervous system, said on Friday it has raised $42 million through a pair of transactions. The company said it generated $27 million from the sale of its TCD Royalty unit, as well as another $15 million from the issuance of venture debt. Supernus said it will use the proceeds to prepare for the commercial launch of its two lead product candidates in epilepsy, as well as to further develop its pipeline. “We have been able to raise more than $165 million through a series of five non-dilutive financing,” said Jack Khattar, the company’s president and CEO.
http://www.supernus.com
http://www.businesswire.com/news/home/20120106005025/en/Supernus-Pharmaceuticals-Raises-42-Million-Prepare-Launch
Roanoke-Based PixelOptics Names Brett Craig as President and CEO
Roanoke, Va. — PixelOptics, a Roanoke-based developer of electronic focusing eyeglasses, has named Brett Craig as its new president and CEO. He succeeds Ronald Blum, who will become chief visionary officer while maintaining his role as chairman. Craig previously served as the president and COO of photochromic lens company Transitions Optical. “Ron’s vision and
leadership were critical elements to bring [the company's technology] from concept to market. Moving forward, Brett’s expertise will be invaluable for the success of the company,” said board member Gary Kurtzman, managing director in the Life Sciences Group at Safeguard Scientifics. PixelOptics’ emPower eyeglasses feature transparent liquid crystal layers in each lens that
electronically focus when needed, with no moving parts. The company last April raised $35 million in a round of equity funding, led by Safeguard Scientifics.
http://www.pixeloptics.com
http://www.empowereyewear.com
http://www.businesswire.com/news/home/20120105006853/en/PixelOptics-Names-Brett-H.-Craig-President-Chief
Mid-Atlantic Bio Welcomes Bio West Virginia and Women In Bio as New 2010 Partners
For the first time, the Bioscience Association of West Virginia (BioWV) and Women In Bio (WIB) will partner with Mid-Atlantic Bio for the 2010 Mid-Atlantic Bio Conference
taking place October 27-29 at the North Bethesda Marriott Convention Center in Bethesda, Md.
As 2010 strategic partners, BioWV and WIB will join event hosts the Tech Council of Maryland/MdBio (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO) to create an even stronger platform for the combined communities of their industry constituents to come together at this year’s conference. Both BioWVA and WIB serve different segments of the expanding biotechnology industry, each important in the industry ecosystem. It is anticipated that both organizations will have strong representation from their respective membership groups at this year’s conference.
The Bioscience Association of West Virginia (BioWV) is that state’s official bioscience organization and is a part of the Council of State Bioscience Associations (CSBA). It serves West Virginia biotech companies with education and helps to increase public awareness of the biotechnology industry in the state.
Women in Bio (WIB) is a national organization dedicated to encouraging entrepreneurship and furthering the career development of women active in the life science industry. WIB is expanding nationally but has its
roots in the Maryland/DC/Virginia corridor.
“We are thrilled to continue building strong alliances with these organizations,” said Mid-Atlantic Venture Association (MAVA) Executive Director Julia Spicer. “We can’t think of two more fitting state and
national partners to welcome to this event, as each share the same deep commitment to bringing some of the best possible resources to their respective industry members and constituents.”
Now in its seventh year, Mid-Atlantic Bio is the only globally-focused, yet regionally-based, event to combine components of a bioscience industry convention with an investor conference under one roof. More
than 800 national and international industry leaders, government representatives, executives, researchers, investors, entrepreneurs, and professional services firms will gather to promote networking, business
expansion, and technical-knowledge sharing. Home to industry-critical regulatory and research agencies; federal policymaking; and business and scientific centers of excellence, the Mid-Atlantic is a unique center for
the global bioscience industry.
Unparalleled Plenary Speakers
The conference brings some of the world’s most noted scientists and executives together all under one roof to provide important access for conference attendees to global thought-leaders. This year’s event offers
a top tier line-up of plenary speakers, unique to this event, including:
- John Castellani, President and CEO, PhRMA
- John F. Crowley, JD, MBA, Chairman and CEO, Amicus Therapeutics
- Frederick Frank, Vice Chairman, Peter J. Solomon Company
- James Greenwood, President and CEO, BIO
- Martine A. Rothblatt, PhD, JD, MBA, Chairman and CEO of United
Therapeutics Corporation
- Joshua M. Sharfstein, MD, Principal Deputy Commissioner, U.S. Food
and Drug Administration
- H. Thomas Watkins, President and CEO, Human Genome Sciences
Valued Timely and Topical Conference Sessions:
Designed as a platform that brings together science, company builders, commercial interests and collaborators, capital sources, and federal and regulatory thought-leaders, the
2010 program
includes a variety of important industry topicsranging from the latest in policy and regulatory matters, business and financing opportunities, and CEO War Stories to advances in science and technologyand showcases exciting companies from the biosciences field. A few of the highlighted sessions include:
- Building a Workforce Culture Around Commercialization
- Corporate Venture and Early Stage Partnerships
- New Science Technologies: Regional Successes
- Drugs and Devices: Reimbursement in a Post-Healthcare Reform World
- Capital Eco-Systems: Formation and International Markets
- An Insider’s View on Washington
- Synthetic Biology Applications and Implications
- Accessing the Regulatory Risk: Your Path to Approval
- CEO War Stories: A Roundtable
Attendees Get a Close Look at the Latest Companies to Watch
Each year at Mid-Atlantic Bio, a select group of life science companies are chosen to present their respective stories before conference attendees, which include an audience of capital sources, including
corporate business development professionals, peer scientists and company leaders, venture capitalists, angel investors, and various other qualified financing sources along with important industry
professionals and potential strategic partners.
BioMatch:
Mid-Atlantic Bio’s signature networking program, BioMatch, is designed specifically for the life sciences and biotech industries, and provides registered attendees access to advanced partnering software that
facilitates personalized, one-on-one meetings between the leading bioscience organizations and industry leaders.
Partial List of Conference Sponsors:
MD Biotechnology Center, MedImmune, Biotechnology Industry Organization, BioMed Realty Trust, Inc., BDO, Alexandria Real Estate Equities, Inc., Janelia Farms Research Campus of Howard Hughes Medical Institute, NIH
Federal Credit Union, George Mason University, Virginia Tech, James Madison University, Broad Oak Partners, H.I.G. BioVentures, CIT Gap Funds, Intersouth Partners, New Enterprises Associates, Oxford Finance,
TEDCO, Third Security, LLC
ABOUT MID-ATLANTIC BIO
The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland/MdBio (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the
Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering
regional associations. For more information, or to register or sponsor, please visit
www.midatlanticbio.org.
# # #
Mid-Atlantic Bio Welcomes Bio West Virginia and Women In Bio Press Release (Full .pdf version)
-->
